ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy

Journal of Nephrology

Volumn 25, Issue 5, 2012, Pages 776-781

  Umruddin, Zia ^a   Moe, Kyaw ^a   Superdock, Keith ^a  

^a LANKENAU HOSPITAL   (United States)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitor; Contrast induced nephropathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CONTRAST MEDIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CASE CONTROL STUDY; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RADIATION EXPOSURE; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; FEMALE; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGED; ODDS RATIO; PENNSYLVANIA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 84867029904     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000059     Document Type: Article

References (23)

1. Turney JH. Acute renal failure: a dangerous condition. JAMA. 1996;275(19):1516-1517.
2. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259-2264.
3. Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant. 2005;20(8):1542-1550.
4. McCullough PA, Soman SS. Contrast-induced nephropathy. Crit Care Clin. 2005;21(2):261-280.
5. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393-1399.
6. Iakovou I, Dangas G, Mehran R, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol. 2003;15(1):18-22.
7. McCullough PA, Adams A, Becker CR, et al. Risk prediction of contrast induced nephropathy. Am J Cardiol. 2006;98(6) (Suppl 1):27-36.
8. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103(5):368-375.
9. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291(19):2328-2334.
10. Caldicott WJ, Hollenberg NK, Abrams HL. Characteristics of response of renal vascular bed to contrast media: evidence for vasoconstriction induced by renin-angiotensin system. Invest Radiol. 1970;5(6):539-547.
11. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J. 1999;51(5):521-526.
12. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95(1):13-19.
13. Rosenstock JL, Bruno R, Kim JK, et al. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrastinduced nephropathy. Int Urol Nephrol. 2008;40(3):749-755.
14. Louis BM, Hoch BS, Hernandez C, et al. Protection from the nephrotoxicity of contrast dye. Ren Fail. 1996;18(4): 639-646.
15. Cirit M, Toprak O, Yesil M, et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract. 2006;104(1):c20-c27.
16. Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL. [The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography]. Anadolu Kardiyol Derg. 2003;3(2):98-103.
17. Onuigbo MA, Onuigbo NT. Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study. Ren Fail. 2008;30(1):67-72.
18. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995; 155(8):829-837.
19. Carter BL, Malone DC, Ellis SL, Dombrowski RC. Antihypertensive Drug Utilization in Hypertensive Veterans With Complex Medication Profiles. J Clin Hypertens (Greenwich). 2000;2(3):172-180.
20. Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension. 2000;36(4):600-603.
21. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mor- tality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327(10):678-684.
22. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118(8):843-849.
23. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008;101(3):279-285.